Concord Biotech Ltd
Concord Biotech Ltd Share Price Today: Live Updates & Key Insights
Get insights on Concord Biotech Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Concord Biotech Ltd Share Price Chart
CONCORDBIO at 10 Jul 2026 06:21 PM Biotechnology
1304.70 -0.70(-0.05%)
Lowest Today 1296.10
Highest Today 1336.50
Today's Open 1311.10
Prev. Close 1305.40
52 Week High 2150.40
52 Week Low 987.00
Concord Biotech Ltd Fundamentals
Traded Volume: 2,02,221
Market Cap(Cr): 13,649.28
Avg Traded Price 1309.41
1 Year return -28.31%
Upper Circuit 1,336.5
Lower Circuit 1,296.1
P/E TTM 52.00
P/B Ratio 6.770
Traded Value(Cr) 2638.38
EPS TTM 24.939
Book value/Share 192.810
Dividend Yield 1Y 0.82%
Concord Biotech Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Concord Biotech Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Concord Biotech Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +1.45%
1M +2.55%
3M +23.70%
1Y -28.31%
YTD -2.31%
Concord Biotech Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Concord Biotech Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.22L
Day Before Yesterday 1.57L
1W Avg 1.17L
1M Avg 2.35L
3M Avg 3.81L
Concord Biotech Ltd Technical Details
Concord Biotech Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1288
Support 2 1272
Support 3 1248
Pivot Point : 1312
Resistance 1 1329
Resistance 2 1353
Resistance 3 1369
Concord Biotech Ltd Corporate Actions
Concord Biotech Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Concord Biotech Ltd’s capital allocation strategies.
All
Ex-Date 03-Sep-2025 Type D Description 10.70/share@1070.00% Record Date 03-Sep-2025 Ratio 1070.00
Ex-Date 21-Jun-2024 Type D Description 8.75/share@875.00% Record Date 22-Jun-2024 Ratio 875.00
Dividends
Announcement Date 03-Sep-2025 Ex Dividend Date 03-Sep-2025 Dividend(%) 1070
Announcement Date 21-Jun-2024 Ex Dividend Date 21-Jun-2024 Dividend(%) 875
Bonus
No Bonus has been declared by CONCORDBIO
Splits
No Split has been declared by CONCORDBIO
Others
Rights No Rights has been declared by CONCORDBIO
Concord Biotech Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Concord Biotech Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Concord Biotech Ltd's relative performance and valuation against major competitors.
Stock Name Biocon Ltd ₹418.50 (+3.70%) M. Cap (Cr) 682.03 1 Yr Return (%) +12.03% P/E (TTM) 176.87 PB Ratio 2.00
Stock Name Concord Biotech Ltd ₹1304.70 (-0.05%) M. Cap (Cr) 136.49 1 Yr Return (%) -28.31% P/E (TTM) 52.31 PB Ratio 6.77
Stock Name Advanced Enzyme Technologies Ltd ₹329.85 (+1.70%) M. Cap (Cr) 36.94 1 Yr Return (%) +1.55% P/E (TTM) 21.89 PB Ratio 2.26
Stock Name Panacea Biotec Ltd ₹546.60 (-1.55%) M. Cap (Cr) 33.48 1 Yr Return (%) +30.52% P/E (TTM) -623.46 PB Ratio 4.01
Stock Name CCME Global Ltd ₹114.95 (-4.96%) M. Cap (Cr) 5.20 1 Yr Return (%) +391.45% P/E (TTM) -209.09 PB Ratio 19.11
Stock Name Alpa Laboratories Ltd ₹68.25 (-0.06%) M. Cap (Cr) 1.44 1 Yr Return (%) -34.30% P/E (TTM) 10.05 PB Ratio 0.77
Stock Name Bharat Immunological & Biological Corporation Ltd ₹17.02 (+2.65%) M. Cap (Cr) 0.73 1 Yr Return (%) -28.49% P/E (TTM) -3.98 PB Ratio 0.84
Concord Biotech Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Concord Biotech Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 263.78 Mar 2025 244.52 Mar 2024 265.47 Mar 2023 246.00
PARTICULARS Investing Activities Mar 2026 -142.28 Mar 2025 -159.99 Mar 2024 -154.61 Mar 2023 -157.95
PARTICULARS Financing Activities Mar 2026 -114.51 Mar 2025 -98.77 Mar 2024 -99.21 Mar 2023 -85.22
PARTICULARS Net Cash Flow Mar 2026 6.98 Mar 2025 -14.24 Mar 2024 11.64 Mar 2023 2.83
Concord Biotech Ltd Shareholding Pattern
This shows the ownership breakdown of Concord Biotech Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 44.08%
Public 38.9%
Other Institutions 4.92%
FII 7.79%
Mutual Funds 4.3%
About Concord Biotech Ltd
Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to `Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market.The Company introduced a new manufacturing unit at Limbasi, and commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale.The Company launched 21 new formulations products in 2025.
Chairman / Executive Director / M D / Promoter
SUDHIR JAIRAM VAID
Registered office 1482-86 Trasad Road, Dholka, Ahmedabad, Gujarat, 382225
FAX :91-079-68138700
Background
Incorporation Year 1984
Face Value ₹1.00
Market Lot 1
FAQs on Concord Biotech Ltd
How to buy Concord Biotech Ltd shares?
To buy Concord Biotech Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Concord Biotech Ltd?
The company has a market capitalization of ₹13,649.28.
What is the PE & PB ratio of Concord Biotech Ltd?
PE is 52 and PB is 6.770.
What is the Concord Biotech Ltd dividend for 2025–26?
For the 2025–26 financial year, Concord Biotech Ltd declared a final dividend of 0.82% per share.